Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
66.54
-1.64 (-2.41%)
At close: May 29, 2026, 4:00 PM EDT
66.65
+0.11 (0.17%)
After-hours: May 29, 2026, 7:31 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Halozyme Therapeutics stock has a consensus rating of "Buy" and an average price target of $83.9. The average 1-year stock price forecast is 26.09% higher than the current stock price, while the lowest is $57 (-14.34%) and the highest is $96 (+44.27%).
Price Target: $83.9 (+26.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 9 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $70 | Hold | Maintains | $70 | +5.20% | May 20, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $75 | Hold | Maintains | $75 | +12.71% | May 14, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $93 → $66 | Buy | Reiterates | $93 → $66 | -0.20% | May 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 | Buy | Reiterates | $95 | +42.77% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $96 | Buy | Maintains | $96 | +44.27% | May 11, 2026 |
Financial Forecast
Revenue This Year
1.81B
from 1.40B
Increased by 29.67%
Revenue Next Year
2.04B
from 1.81B
Increased by 12.59%
EPS This Year
8.28
from 2.56
Increased by 223.53%
EPS Next Year
10.03
from 8.28
Increased by 21.12%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.9B | 2.1B | ||||||
| Avg | 1.8B | 2.0B | ||||||
| Low | 1.7B | 1.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 36.2% | 18.6% | ||||||
| Avg | 29.7% | 12.6% | ||||||
| Low | 22.9% | 4.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 8.62 | 10.52 | ||||||
| Avg | 8.28 | 10.03 | ||||||
| Low | 7.88 | 9.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 236.7% | 27.0% | ||||||
| Avg | 223.5% | 21.1% | ||||||
| Low | 207.8% | 12.3% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.